Direct RNA Sequencing RNA Input: RIN, Quantity, Pitfalls Checklist

At a glance:

• DRS Fails Fast: Why RNA Input QC Determines Everything
• One-Page Acceptance Criteria: What "Pass" Looks Like Before You Start
• Step-by-Step DRS RNA Input Checklist
• How to Read RIN (and When to Use DV200 or Electropherogram Patterns Instead)
• Quantity Requirements: Total Mass, Not Just Concentration
• The Top 10 DRS RNA Pitfalls (Symptoms → Causes → Fixes → Reject Gates)
• Clinical and Low-Input Samples: What Changes, What Doesn't
• FAQ: DRS RNA Input, RIN, and QC Thresholds
• Next Steps: Plan a Low-Risk Run and Validate Expectations

Direct RNA sequencing(DRS) fails fast when input quality is off. Minor upstream issues—like a low A260/230 or a marginal RIN—rarely self-correct later. This checklist distills pass/conditional/reject gates so core facilities can set auditable thresholds and technicians can execute with confidence.

Assumptions & Boundaries

• Scope: nanopore-based direct RNA sequencing of native RNA; platform-agnostic phrasing and no device-specific yield promises.
• Outcomes: we describe directional trends (e.g., degraded inputs shift read-length distributions left) rather than guarantees.
• Evidence window: 2019–2026 references from official protocols and peer‑reviewed or vendor bench guides.

Key takeaways

• DRS RNA input quality defines outcomes: think total mass, purity, and integrity—not concentration alone.
• Use fluorometric quantification (Qubit/RiboGreen) for mass decisions; use absorbance only for purity screening.
• Purity gates: A260/280 ～1.9–2.1; A260/230 ～2.0–2.2 typical; ≥1.8 minimum. ≤1.5 is a hard reject unless remediated.
• Integrity gates: RIN ≥7 preferred (6–7 conditional). For FFPE or known fragmentation, prioritize DV200: ≥50% proceed; 30–50% conditional; <30% reject/switch.
• Handling matters: ≤1 freeze–thaw preferred; 2 with risk disclosure; ≥3 is high risk for long isoforms.

DRS Fails Fast: Why RNA Input QC Determines Everything

When DRS inputs are even slightly off, the workflow rarely compensates. Inhibitors depress ligation/loading efficiency, fragmented RNA collapses read lengths, and mismatched quantification leads to underloaded runs. The fix is upstream: set clear acceptance gates for the DRS RNA input, verify before committing, and stop early when samples fall outside remediation windows. According to the publisher's overview in the Guidelines for RNA Quantitation by NEB (2024), fluorometric assays offer more reliable mass estimates than absorbance in the presence of contaminants—exactly the situation that leads to failed runs in native RNA workflows.

One-Page Acceptance Criteria: What "Pass" Looks Like Before You Start

High-quality samples (fresh tissue, cultured cells, PBMC)

• Quantification: Fluorometric baseline (Qubit/RiboGreen). Absorbance is for ratios only.
• Purity: A260/280 1.9–2.1; A260/230 2.0–2.2 typical; ≥1.8 minimum. ≤1.5 → Reject or re-extract.
• Integrity: RIN ≥7 preferred; 6–7 Conditional proceed (declare risks). <6 → High risk path.
• Mass: Total RNA 1 µg or poly(A) RNA 300 ng (platform-level starting point), consistent with the inputs summarized in Oxford Nanopore's Direct RNA SQK‑RNA004 protocol.
• Handling: Freeze–thaw ≤1 Proceed; 2 Conditional (expect shorter reads); ≥3 High risk.

Fragmented/clinical challenging samples

• Keep fluorometry for mass. Purity must be ≥1.8 to Proceed; <1.8 with failed cleanup → Switch strategy.
• Integrity: Read electropherogram patterns (rRNA peaks vs smear; long-fragment fraction). Don't rely on RIN alone.

FFPE or highly fragmented samples (use DV200)

• DV200 ≥50% Proceed.
• DV200 30–50% Conditional: increase input, lower expectations, or consider hybrid/cDNA workflows.
• DV200 &lt;30% — Reject or switch strategy. Conservative gates are supported by peer‑reviewed DV200 analyses showing improved library and sequencing outcomes at higher DV200 values for degraded RNA.

Low-input samples (scarce RNA)

• Recommended: 1 µg total or 300 ng poly(A) for robust DRS RNA input.
• Conditional proceed below these masses only with documented lower yield/read-length expectations and added replicates.
• Mitigate losses: low‑bind plastics, minimal transfers; consider carrier where appropriate.

Matrix notes

• Heparinized blood/plasma: high inhibitor risk; if removal fails, switch strategy.
• PBMC: follow high‑quality path; RNase control and minimal freeze–thaw are key.
• Salt/organic carryover: use A260/230 as the alarm; clean up before run.

Tip: Cleaner inputs generally support more reliable modification detection; see the CD Genomics knowledge page Direct RNA Sequencing Methylation Detection.

Step-by-Step DRS RNA Input Checklist

1. Sample metadata

• Record matrix, collection tubes/anticoagulant, storage temperature, time‑to‑freeze, and freeze–thaw count. Flag heparin explicitly.

2. Quantification (mass decisions)

• Measure with Qubit/RiboGreen. Calculate total mass available. If NanoDrop and Qubit disagree, trust fluorometry and suspect contaminants or gDNA.

3. Purity screening (red‑flag ratios)

• A260/280 1.9–2.1 and A260/230 2.0–2.2 typical; ≥1.8 minimum to proceed.
• 1.5–1.8: Perform cleanup (column/bead), dry thoroughly, re‑measure. Proceed only if improved to ≥1.8.
• ≤1.5: Reject or re‑extract; inhibitors likely to impair ligation/loading.

• Bioanalyzer/TapeStation: Examine rRNA peaks vs smear; assign RIN. Practical interpretation guidance is outlined in Agilent's RNA analysis white paper (2022).
• For FFPE/degraded: Use DV200 as the primary gate (≥50% proceed; 30–50% conditional; <30% reject/switch) per DV200.

5. Optional checks

• DNA contamination: Look for high‑MW bump; run no‑RT control. Apply DNase with proper removal and verify.
• Inhibitor suspicion list: phenol/guanidine, salts, residual ethanol, heparin.

6. Packing and shipping

• Aliquot to avoid repeat thaws; ship on dry ice early in the week; include a manifest and temperature log. Maintain RNase‑free handling.

7. Decision gate

• Proceed: meets purity and integrity gates; mass at or above recommended.
• Conditional proceed: slightly low integrity (RIN 6–7 or DV200 30–50%) or low mass; declare lower expectations and add replicates.
• Reject/switch: purity ≤1.5 after cleanup, DV200 <30%, or repeated freeze–thaw (≥3) for long‑isoform goals.

Practical outsourcing example

• Some cores validate acceptance gates with a small pilot. A neutral approach is to send a mixed batch (high‑quality, borderline DV200, low‑input) for an external QC review and limited DRS run. A provider like CD Genomics can help confirm mass/purity thresholds, shipping logistics, and bench‑to‑bioinformatics handoff without committing a full cohort. Keep expectations conservative, document gates, and adjust your local SOP accordingly.

How to Read RIN (and When to Use DV200 or Electropherogram Patterns Instead)

RIN is helpful for intact total RNA, but it's not universal. Clean eukaryotic rRNA peaks (28S/18S) with a low baseline typically indicate RIN ≥7 and a healthy long‑fragment fraction. A smeared profile and reduced 28S:18S ratio indicate progressive degradation and a left‑shifted read‑length distribution. For FFPE or known fragmentation, DV200 outperforms RIN as a predictor of usable RNA: ≥50% generally supports Proceed, 30–50% is Conditional, and <30% predicts frequent failure or impractically short reads. For why integrity matters so much for isoforms and native modifications, see the CD Genomics explainer Direct RNA Sequencing: Technology, Applications, and Future.

Rules‑of‑thumb

• Borderline but usable: RIN 6–7 with clean purity and no inhibitor flags; DV200 30–50% with increased input and tempered expectations.
• High risk: RIN <6 for long‑isoform goals; DV200 <30%; persistent low A260/230 after cleanup.

Quantity Requirements: Total Mass, Not Just Concentration

The control variable is total input mass in the library step, not the concentration in the tube. A "concentrated" sample with little total mass still underloads your run. As a robust starting point for DRS RNA input, plan for 1 µg total RNA or about 300 ng poly(A) RNA, which aligns with inputs summarized in Oxford Nanopore's SQK‑RNA004 documentation.

When you're short on mass, decide early:

• Concentrate vs re‑extract: If purity is good, concentration via column/bead kits works; avoid over‑drying.
• Pooling strategy: Pool multiple extractions/replicates to de‑risk borderline inputs.
• Stop points: Below the recommended mass, only continue if you've documented lower yield/read‑length expectations and added replicates for your analysis goals.

Why fluorometry wins

• Absorbance at 260 nm is non‑specific and inflates concentration when contaminants or DNA are present. Fluorometric assays selectively bind nucleic acids and are more reliable for mass decisions.

The Top 10 DRS RNA Pitfalls (Symptoms → Causes → Fixes → Reject Gates)

1. Low A260/230

• Cause: phenol/guanidine, salts, residual ethanol.
• Fix: Column/bead cleanup; extra washes; complete drying; re‑measure.
• Reject: ≤1.5 after cleanup attempts.

2. High NanoDrop, low Qubit

• Cause: contaminants/gDNA inflating absorbance.
• Fix: DNase treatment; cleanup; trust fluorometry for mass decisions.

3. Genomic DNA contamination

• Symptom: high‑MW bump on electropherogram; inflated mass.
• Fix: DNase with proper removal; verify by no‑RT control.

4. RNase exposure

• Symptom: smear; RIN drop; shortened read lengths.
• Fix: RNase‑free workflow; stabilize and process on ice.

5. Repeated freeze–thaw

• Symptom: progressive fragmentation; integrity decline.
• Fix: Aliquot; limit thaws; thaw on ice.

6. Harsh lysis/mixing

• Symptom: mechanical shearing; smear.
• Fix: Gentle homogenization; validate integrity post‑extraction.

7. Salt carryover

• Symptom: low A260/230; ligation inefficiency risk.
• Fix: Extra ethanol washes; ensure full dry; buffer optimization.

8. Residual ethanol

• Symptom: inhibition; low A260/230.
• Fix: Full‑speed spins; extend drying; repeat wash if needed.

9. Under/over DNase treatment

• Symptom: residual gDNA or RNA nicking.
• Fix: Correct DNase protocol and complete removal; avoid heat‑only inactivation.

10. Tube/plastic adsorption (low-input)

• Symptom: poor recovery; apparent mass loss.
• Fix: Low‑bind plastics; minimize transfers; consider carrier where appropriate.

For readers focused on modification confidence (e.g., m6A, pseudouridine), cleaner inputs and intact molecules help reduce false negatives/positives in signal calling. See the knowledge page Direct RNA Sequencing Methylation Detection for boundaries and confidence.

Clinical and Low-Input Samples: What Changes, What Doesn't

What changes

• Inhibitors are more common (heparin, heme, salts). If removal fails without degrading RNA, switch strategy.
• Fragmentation is typical; expect a left‑shifted read‑length distribution even after cleanup.

What doesn't

• Purity thresholds still rule: aim for A260/230 ≥1.8; reject ≤1.5.
• DV200 guides usability better than RIN when degradation is known.

Handling priorities

• Time‑to‑freeze; single thaw cycle; RNase control; documented chain‑of‑custody.

Switch strategy rules

• DV200 <30% → reject/switch to cDNA long‑read or a hybrid strategy (native + cDNA).
• A260/230 ≤1.5 or 1.5–1.8 unremediated → switch.
• Input below recommended mass → conditional proceed only with declared expectations and replicates.

If you're balancing isoform presence vs modification calling depth, consider piloting both native and cDNA long‑read paths on a small subset first.

FAQ: DRS RNA Input, RIN, and QC Thresholds

• What RIN is typically acceptable for DRS?
  • RIN ≥7 is preferred; 6–7 is usable with risk disclosure. Below 6, treat as high risk for long isoforms.
• When should I use DV200 instead of RIN?
  • For FFPE or known degraded RNA. DV200 ≥50% proceeds; 30–50% is conditional; <30% reject/switch.
• Why do absorbance and fluorometric quantification disagree?
  • Absorbance is non‑specific and inflated by contaminants and gDNA. Use fluorometry for mass decisions.
• What purity ratios most often predict failure risk?
  • A260/280 <1.8 (proteins/phenol) and A260/230 <1.8 (salts/organics). ≤1.5 strongly predicts inhibition.
• How do freeze–thaw cycles affect DRS output?
  • Each cycle fragments RNA. Prefer ≤1; at 2, disclose risk; ≥3 is high risk for long isoforms.
• Can I proceed with borderline RNA if I only need isoforms or modifications?
  • Yes, conditionally: ensure purity ≥1.8 and DV200 ≥30%, lower expectations, and add replicates.

Next Steps: Plan a Low-Risk Run and Validate Expectations

• Align acceptance gates with your throughput plan and stop points. Pilot a small batch to validate purity/integrity gates and shipping/handling steps before scaling cohorts. If you care about modification confidence, review boundaries in Direct RNA Sequencing Methylation Detection.
• A provider such as CD Genomics can support a low‑risk pilot and QC review to translate these gates into a working SOP for your matrix and goals. Keep the scope modest, document outcomes, and iterate.

The CD Genomics Long‑Read Team is the article author and contributor. The team is a core sequencing group within CD Genomics with decades of collective genomics service experience and hands‑on expertise in native long‑read RNA workflows. Their responsibilities include sample QC, library preparation, sequencing operations, and long‑read bioinformatics for DRS projects; they regularly advise core facilities on SOPs, pilot QC runs, and bench‑to‑analysis handoffs. Learn more at the CD Genomics Long‑Read Services page: .

Poly(A) Tail Length Analysis

Full-Length Transcript Sequencing (Iso-Seq)

Nanopore Direct RNA Sequencing

Nanopore Full-Length cDNA Sequencing